Olympus had agreed to sell its microscope unit to private equity firm Bain Capital for $3.1 billion as it speeds up the overhaul of its business portfolio to focus solely on medical technology
The microscope unit, which also manufactures industrial endoscopes and x-ray analyzers, will be transferred to Bain on January 4, subject to antitrust regulatory approvals in Japan and elsewhere.
Olympus stated that the transfer to Bain would benefit the company by allowing it to grow through more agile and flexible decision-making based on market needs.
Bain edged global private equity firms such as Carlyle Group and KKR & Co. for the right to acquire the microscope unit.
Olympus said the transfer to Bain would be in its best interest to allow the business to grow with more agile and flexible decision-making based on market needs.
Bain won over global private equity firms such as Carlyle Group and KKR & Co.
Bain owns flash memory chip maker Kioxia Holdings and is proceeding to a second bidding round for Toshiba.


NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
US Launches New Trade Investigation Into Vietnam Over Intellectual Property Concerns
ECB’s Philip Lane Warns Middle East Conflict Could Keep Inflation Elevated
US Imposes Fresh Iran Oil Sanctions Despite Progress on Ceasefire Talks
Neuralink Expands Brain Implant Trials with 12 Global Patients
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026
Wall Street Hits New Highs as U.S.-Iran Ceasefire Talks Boost Market Sentiment
U.S. Launches New Strikes on Iran as Trump Signals Peace Deal Uncertainty
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target
Dollar Gains Slightly as U.S.-Iran Tensions Keep Forex Markets on Edge
Universal Music Group Rejects Pershing Square Takeover Proposal 



